AusCann Group Holdings’
(ASX:AC8) strategic partner, Tasmanian Alkaloids Pty Ltd, has been granted a medicinal cannabis and a research and development licence from the Office of Drug Control.
The Australasian medical cannabis company and Tasmanian Alkaloids Pty Ltd entered into a partnership in May 2017 to jointly establish, cultivate, manufacture and distribute medical cannabis in Australia and overseas.
AusCann says the licences are a significant milestone in their partnership.
Their alliance is now well placed to become a leading supplier of Australian produced, high quality, clinically validated and affordable medicinal cannabis for Australian patients.
Shares in AusCann Group Holdings
(ASX:AC8) last traded over 2.3 per cent lower yesterday to 42.5 cents.
